{"disease":{"id":"vaginal-candidiasis","name":"vaginal candidiasis"},"drugs":{"marketed":[{"drug_id":"fluconazole","indication_name":"Vaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"butoconazole-nitrate","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUTOCONAZOLE NITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"ibrexafungerp-citrate","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP CITRATE","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"oteseconazole","indication_name":"Recurrent vulvovaginal candidiasis (RVVC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vivjoa","generic_name":"OTESECONAZOLE","company_name":"Mycovia Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Azole Antifungal [EPC]","quality_score":58,"revenue":null,"mechanism":"Vivjoa works by inhibiting the enzyme Cytochrome P450 3A4, which is involved in the synthesis of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"ibrexafungerp","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":27,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT07044947","title":"Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT05079711","title":"Comparative Performance of a Vaginal Yeast Test","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Uniformed Services University of the Health Sciences","has_results":false},{"nct_id":"NCT03045809","title":"Women's Improvement of Sexual Health (WISH) Demonstration Project","phase":"","overall_status":"COMPLETED","enrollment_count":705,"lead_sponsor_name":"Janneke van de Wijgert","has_results":true},{"nct_id":"NCT04029116","title":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03562156","title":"A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04734405","title":"A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":432,"lead_sponsor_name":"ProFem GmbH","has_results":false},{"nct_id":"NCT03561701","title":"A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04956419","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":322,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06835361","title":"Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":264,"lead_sponsor_name":"AVVA Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT02267382","title":"A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Viamet","has_results":true},{"nct_id":"NCT06190509","title":"Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"LimmaTech Biologics AG","has_results":false},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03840616","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT06411314","title":"Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Avva Rus, JSC","has_results":false},{"nct_id":"NCT05074602","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":196,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06450990","title":"Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":165,"lead_sponsor_name":"NEXBIOME THERAPEUTICS","has_results":false},{"nct_id":"NCT01806623","title":"The Study Of Fluconazole For Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05399641","title":"Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT04699240","title":"Study of Lactobacillus in Adjuvant Treatment of RVVC","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Peking University Shenzhen Hospital","has_results":false},{"nct_id":"NCT06474247","title":"Postbiotic as Adjunct Treatment for Vaginal Candidiasis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Min-Tze LIONG","has_results":false},{"nct_id":"NCT02866227","title":"TOL-463 Phase 2 Study for Vaginitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Toltec Pharmaceuticals, LLC","has_results":false},{"nct_id":"NCT05908682","title":"Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Scynexis, Inc.","has_results":false},{"nct_id":"NCT03115073","title":"ProF-001_Phase IIa","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"ProFem GmbH","has_results":false},{"nct_id":"NCT07234786","title":"Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Karo Pharma AB","has_results":false},{"nct_id":"NCT05895162","title":"Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"FEMPHARMA Kft.","has_results":false},{"nct_id":"NCT04208555","title":"Comparison of Boric Acid vs. Terconazole in Treatment of RVVC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"Hatem AbuHashim","has_results":false},{"nct_id":"NCT04639544","title":"Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"Biosearch S.A.","has_results":false},{"nct_id":"NCT03473418","title":"Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05795491","title":"Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06983041","title":"Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Coologics, Inc","has_results":false},{"nct_id":"NCT05552378","title":"Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Karo Pharma AB","has_results":false},{"nct_id":"NCT05507333","title":"Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Gedea Biotech AB","has_results":true},{"nct_id":"NCT03761628","title":"Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Gedea Biotech AB","has_results":true},{"nct_id":"NCT05753813","title":"Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Queen's Medical Center","has_results":false},{"nct_id":"NCT01915251","title":"Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women","phase":"","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05327192","title":"VVC Sampling Study for Analysis Validation","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Gedea Biotech AB","has_results":false},{"nct_id":"NCT06954493","title":"Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Scynexis, Inc.","has_results":true}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}